NCT01357252 - Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes | Biotech Hunter

Enrollment

279

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

vildagliptin

DRUG

Placebo

Trial Locations (18)

100029

Novartis Investigative Site, Beijing

100034

Novartis Investigative Site, Beijing

100088

Novartis Investigative Site, Beijing

100730

Novartis Investigative Site, Beijing

110003

Novartis Investigative Site, Shenyang

200040

Novartis Investigative Site, Shanghai

200233

Novartis Investigative Site, Shanghai

210006

Novartis Investigative Site, Nanjing

210008

Novartis Investigative Site, Nanjing

210029

Novartis Investigative Site, Nanjing

212001

Novartis Investigative Site, Zhenjiang

300211

Novartis Investigative Site, Tianjin

410003

Novartis Investigative Site, Changsha

430070

Novartis Investigative Site, Wuhan

510080

Novartis Investigative Site, Guangzhou

050051

Novartis Investigative Site, Shijiazhuang

Unknown

Novartis Investigative Site, Shanghai

Novartis Investigative Site, Beijing